JP2013513586A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013513586A5 JP2013513586A5 JP2012542577A JP2012542577A JP2013513586A5 JP 2013513586 A5 JP2013513586 A5 JP 2013513586A5 JP 2012542577 A JP2012542577 A JP 2012542577A JP 2012542577 A JP2012542577 A JP 2012542577A JP 2013513586 A5 JP2013513586 A5 JP 2013513586A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- carbon atoms
- active ingredient
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 150000002430 hydrocarbons Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229930105110 Cyclosporin A Natural products 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000006184 cosolvent Substances 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09015423.8 | 2009-12-14 | ||
| EP09015423A EP2335735A1 (en) | 2009-12-14 | 2009-12-14 | Pharmaceutical composition for treatment of dry eye syndrome |
| PCT/EP2010/069495 WO2011073134A1 (en) | 2009-12-14 | 2010-12-13 | Pharmaceutical composition for treatment of dry eye syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014203406A Division JP6096731B2 (ja) | 2009-12-14 | 2014-10-01 | ドライアイ症候群の治療のための医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013513586A JP2013513586A (ja) | 2013-04-22 |
| JP2013513586A5 true JP2013513586A5 (https=) | 2014-01-09 |
| JP5663595B2 JP5663595B2 (ja) | 2015-02-04 |
Family
ID=41731659
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012542577A Active JP5663595B2 (ja) | 2009-12-14 | 2010-12-13 | ドライアイ症候群の治療のための医薬組成物 |
| JP2014203406A Active JP6096731B2 (ja) | 2009-12-14 | 2014-10-01 | ドライアイ症候群の治療のための医薬組成物 |
| JP2016248533A Active JP6397472B2 (ja) | 2009-12-14 | 2016-12-22 | ドライアイ症候群の治療のための医薬組成物 |
| JP2018163569A Pending JP2019006803A (ja) | 2009-12-14 | 2018-08-31 | ドライアイ症候群の治療のための医薬組成物 |
| JP2018248700A Active JP6731039B2 (ja) | 2009-12-14 | 2018-12-28 | ドライアイ症候群の治療のための医薬組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014203406A Active JP6096731B2 (ja) | 2009-12-14 | 2014-10-01 | ドライアイ症候群の治療のための医薬組成物 |
| JP2016248533A Active JP6397472B2 (ja) | 2009-12-14 | 2016-12-22 | ドライアイ症候群の治療のための医薬組成物 |
| JP2018163569A Pending JP2019006803A (ja) | 2009-12-14 | 2018-08-31 | ドライアイ症候群の治療のための医薬組成物 |
| JP2018248700A Active JP6731039B2 (ja) | 2009-12-14 | 2018-12-28 | ドライアイ症候群の治療のための医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8614178B2 (https=) |
| EP (2) | EP2335735A1 (https=) |
| JP (5) | JP5663595B2 (https=) |
| KR (2) | KR101652714B1 (https=) |
| CN (1) | CN102652022B (https=) |
| AU (1) | AU2010333039B2 (https=) |
| BR (3) | BR122017018955B1 (https=) |
| CA (2) | CA2941956C (https=) |
| DK (1) | DK2512515T3 (https=) |
| ES (1) | ES2449308T3 (https=) |
| IN (1) | IN2012DN03128A (https=) |
| MX (1) | MX2012006720A (https=) |
| PL (1) | PL2512515T3 (https=) |
| PT (1) | PT2512515E (https=) |
| WO (1) | WO2011073134A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2437684B1 (en) | 2009-06-03 | 2022-06-15 | ForSight Vision5, Inc. | Anterior segment drug delivery |
| PL2547323T3 (pl) | 2010-03-17 | 2016-07-29 | Novaliq Gmbh | Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| JP6023181B2 (ja) | 2011-05-25 | 2016-11-09 | ノバリック ゲーエムベーハー | 爪に投与するための医薬組成物 |
| DK2714010T3 (en) | 2011-05-25 | 2017-06-12 | Novaliq Gmbh | TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORED ALKANES |
| KR101989648B1 (ko) * | 2012-01-23 | 2019-06-14 | 노바리크 게엠베하 | 부분불소화 알칸에 기초한 안정화된 단백질 조성물 |
| CN113679699B (zh) | 2012-09-12 | 2022-10-28 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| AU2013314303B2 (en) * | 2012-09-12 | 2018-01-18 | Novaliq Gmbh | Semifluorinated alkane compositions |
| DK2708228T3 (en) | 2012-09-12 | 2018-08-20 | Novaliq Gmbh | COMPOSITION FOR EYE RINSE |
| EP2730291A1 (en) * | 2012-11-09 | 2014-05-14 | Fluoron Gmbh | Internal Tamponade Composition |
| AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
| JP6304475B2 (ja) * | 2013-01-31 | 2018-04-04 | ロート製薬株式会社 | 点眼剤 |
| CN105073112B (zh) * | 2013-03-13 | 2017-12-29 | 参天制药株式会社 | 睑板腺功能障碍的治疗剂 |
| PT3024484T (pt) | 2013-07-23 | 2018-10-24 | Novaliq Gmbh | Composições de anticorpo estabilizadas |
| EP3057514A4 (en) * | 2013-10-15 | 2017-08-02 | Forsight Vision5, Inc. | Formulations and methods for increasing or reducing mucus |
| US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
| US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
| US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
| US11013403B2 (en) * | 2015-09-29 | 2021-05-25 | The Regents Of The University Of California | Methods of diagnosing diseases of mucosal surfaces |
| US11154513B2 (en) * | 2015-09-30 | 2021-10-26 | Novaliq Gmbh | Semifluorinated compounds |
| CN110403923B (zh) * | 2015-09-30 | 2021-09-21 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| PT3442480T (pt) | 2016-06-23 | 2019-12-23 | Novaliq Gmbh | Método de administração tópica |
| CA3036297C (en) | 2016-09-22 | 2023-09-05 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| WO2018055101A1 (en) | 2016-09-23 | 2018-03-29 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| AU2017333420A1 (en) * | 2016-09-28 | 2019-04-04 | Novaliq Gmbh | Compositions comprising a cannabinoid receptor binding ligand |
| BR112019012568A2 (pt) * | 2016-12-22 | 2019-11-26 | Novaliq Gmbh | composições compreendendo tacrolimus para o tratamento de doenças intraoculares inflamatórias |
| EP4374851B1 (en) * | 2016-12-23 | 2026-04-15 | Novaliq GmbH | Ophthalmic composition for treatment of dry eye disease |
| EP3565520B1 (en) | 2017-01-06 | 2026-02-25 | Palvella Therapeutics, Inc. | Anhydrous compositions of mtor inhibitors and methods of use |
| CA3058097C (en) | 2017-04-21 | 2024-01-02 | Novaliq Gmbh | Iodine compositions |
| WO2018202835A1 (en) | 2017-05-05 | 2018-11-08 | Novaliq Gmbh | Process for the production of semifluorinated alkanes |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| MX2020003534A (es) | 2017-09-27 | 2020-07-29 | Novaliq Gmbh | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. |
| WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
| KR20200128407A (ko) | 2018-03-02 | 2020-11-12 | 노바리크 게엠베하 | 네비볼롤을 포함하는 약제학적 조성물 |
| SG11202007860XA (en) | 2018-03-28 | 2020-09-29 | Novaliq Gmbh | Pharmaceutical composition comprising timolol |
| CN112153970A (zh) | 2018-04-27 | 2020-12-29 | 诺瓦利克有限责任公司 | 用于治疗青光眼的包含他氟前列素的眼用组合物 |
| US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
| WO2020058504A1 (en) * | 2018-09-22 | 2020-03-26 | Novaliq Gmbh | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness |
| EP3856124A1 (en) | 2018-09-27 | 2021-08-04 | Novaliq GmbH | Lipid barrier repair |
| SG11202102820VA (en) * | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| WO2020152046A1 (en) * | 2019-01-21 | 2020-07-30 | Novaliq Gmbh | Pharmaceutical composition for the treatment of ocular neovascularisation |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| WO2020239646A1 (en) | 2019-05-24 | 2020-12-03 | Novaliq Gmbh | Ophthalmic composition for the treatment of ocular allergy |
| KR20220058577A (ko) | 2019-09-06 | 2022-05-09 | 노바리크 게엠베하 | 포도막염 치료를 위한 안과용 조성물 |
| WO2021048803A1 (en) | 2019-09-13 | 2021-03-18 | Minas Coroneo | Eye drop dispenser |
| WO2021191273A1 (en) | 2020-03-24 | 2021-09-30 | Hovione Scientia Limited | Compositions for use in treating meibomian gland dysfunction |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| IL322635A (en) * | 2023-02-13 | 2025-10-01 | Novaliq Gmbh | Ophthalmic preparation for eye surgery in patients with ocular surface disease |
| AU2023270196B2 (en) * | 2023-11-20 | 2025-06-26 | Dyer, Gordon Wayne DR | Method of Arthropod Egress |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR920003601B1 (ko) | 1987-09-03 | 1992-05-04 | 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 | 점안 싸이클로스포린(cyclosporin)의 조성물 |
| US4839342A (en) | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
| US5874481A (en) * | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
| DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| DE19861012A1 (de) * | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
| WO2000066122A1 (en) * | 1999-04-30 | 2000-11-09 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
| DE19938668B4 (de) * | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| WO2005099718A1 (en) * | 2004-04-19 | 2005-10-27 | Centre National De La Recherche Scientifique (C.N.R.S.) | Lung surfactant supplements |
| MXPA06014425A (es) * | 2004-06-08 | 2007-05-23 | Ocularis Pharma Inc | Composiciones oftalmicas hidrofobas y metodo de uso. |
| DE102007055046A1 (de) * | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | Infusionslösung |
| ES2377152T3 (es) | 2008-04-18 | 2012-03-22 | Novaliq Gmbh | Uso inhalativo e instilativo de alcanos semifluorados como vehículos de principios activos en la región intrapulmonar |
-
2009
- 2009-12-14 EP EP09015423A patent/EP2335735A1/en not_active Withdrawn
-
2010
- 2010-12-13 KR KR1020127018066A patent/KR101652714B1/ko active Active
- 2010-12-13 BR BR122017018955-7A patent/BR122017018955B1/pt active IP Right Grant
- 2010-12-13 PT PT107907750T patent/PT2512515E/pt unknown
- 2010-12-13 CN CN201080055507.7A patent/CN102652022B/zh active Active
- 2010-12-13 WO PCT/EP2010/069495 patent/WO2011073134A1/en not_active Ceased
- 2010-12-13 US US13/513,886 patent/US8614178B2/en active Active
- 2010-12-13 AU AU2010333039A patent/AU2010333039B2/en active Active
- 2010-12-13 CA CA2941956A patent/CA2941956C/en active Active
- 2010-12-13 DK DK10790775.0T patent/DK2512515T3/en active
- 2010-12-13 JP JP2012542577A patent/JP5663595B2/ja active Active
- 2010-12-13 IN IN3128DEN2012 patent/IN2012DN03128A/en unknown
- 2010-12-13 EP EP10790775.0A patent/EP2512515B1/en active Active
- 2010-12-13 PL PL10790775T patent/PL2512515T3/pl unknown
- 2010-12-13 KR KR1020167023214A patent/KR101722039B1/ko active Active
- 2010-12-13 BR BR122020020872-4A patent/BR122020020872B1/pt active IP Right Grant
- 2010-12-13 ES ES10790775.0T patent/ES2449308T3/es active Active
- 2010-12-13 MX MX2012006720A patent/MX2012006720A/es active IP Right Grant
- 2010-12-13 BR BR112012014190A patent/BR112012014190B8/pt active IP Right Grant
- 2010-12-13 CA CA2776860A patent/CA2776860C/en active Active
-
2014
- 2014-10-01 JP JP2014203406A patent/JP6096731B2/ja active Active
-
2016
- 2016-12-22 JP JP2016248533A patent/JP6397472B2/ja active Active
-
2018
- 2018-08-31 JP JP2018163569A patent/JP2019006803A/ja active Pending
- 2018-12-28 JP JP2018248700A patent/JP6731039B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013513586A5 (https=) | ||
| JP2013540140A5 (https=) | ||
| JP2013518056A5 (https=) | ||
| ES2717204T3 (es) | Compuestos aminoesteroideos para una aplicación tópica local para la descolonización cutáneo-mucosa de Staphylococcus aureus | |
| JP2019529457A5 (https=) | ||
| JP2009544722A5 (https=) | ||
| JP2013511496A5 (https=) | ||
| JP2020517622A (ja) | ヨウ素組成物 | |
| JP2013542247A5 (https=) | ||
| JP2010077141A5 (https=) | ||
| JP6076267B2 (ja) | リファキシミンの形態およびその使用 | |
| JP2009102342A5 (https=) | ||
| TW200825094A (en) | Therapeutic pyrazolyl thienopyridines | |
| JP2011201907A5 (https=) | ||
| JP2013518036A5 (https=) | ||
| HRP20151000T1 (hr) | Antivirusni spojevi | |
| JP2014516942A5 (https=) | ||
| HRP20211762T1 (hr) | Derivati benzoksaborola za liječenje bakterijskih infekcija | |
| JP2013512277A5 (https=) | ||
| US20160090600A1 (en) | Composition for external application comprising transcription factor decoy as active ingredient | |
| JP2014508804A5 (https=) | ||
| CO6400138A2 (es) | Compuesto anticancerígeno y composición farmacéutica que lo contiene | |
| JP2008501760A5 (https=) | ||
| AR076300A1 (es) | Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades. | |
| WO2008093059A1 (en) | Basic peptides and their use as combined antibacterial-antifungine agents |